CN116622670A - Bacillus cereus ATP synthase beta subunit antibacterial peptide BaD and application thereof - Google Patents
Bacillus cereus ATP synthase beta subunit antibacterial peptide BaD and application thereof Download PDFInfo
- Publication number
- CN116622670A CN116622670A CN202310034176.8A CN202310034176A CN116622670A CN 116622670 A CN116622670 A CN 116622670A CN 202310034176 A CN202310034176 A CN 202310034176A CN 116622670 A CN116622670 A CN 116622670A
- Authority
- CN
- China
- Prior art keywords
- antibacterial peptide
- bad
- antibacterial
- bacillus cereus
- atp synthase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 113
- 241000193755 Bacillus cereus Species 0.000 title claims abstract description 30
- 241000607272 Vibrio parahaemolyticus Species 0.000 claims abstract description 48
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 31
- 241000191984 Staphylococcus haemolyticus Species 0.000 claims abstract description 29
- 229940037649 staphylococcus haemolyticus Drugs 0.000 claims abstract description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 19
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 15
- 239000003674 animal food additive Substances 0.000 claims abstract description 12
- 239000005452 food preservative Substances 0.000 claims abstract description 10
- 235000019249 food preservative Nutrition 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 28
- 230000002147 killing effect Effects 0.000 claims description 13
- 239000003242 anti bacterial agent Substances 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 8
- 229940124350 antibacterial drug Drugs 0.000 claims description 4
- 238000009360 aquaculture Methods 0.000 claims description 2
- 244000144974 aquaculture Species 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 21
- 241000894006 Bacteria Species 0.000 description 17
- 230000001580 bacterial effect Effects 0.000 description 16
- 210000000170 cell membrane Anatomy 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 10
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 10
- 239000008363 phosphate buffer Substances 0.000 description 7
- 108020000946 Bacterial DNA Proteins 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 101100379209 Arabidopsis thaliana APD3 gene Proteins 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 101710169645 ATP synthase subunit beta Proteins 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000013379 Mitochondrial Proton-Translocating ATPases Human genes 0.000 description 2
- 108010026155 Mitochondrial Proton-Translocating ATPases Proteins 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000001142 circular dichroism spectrum Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000003345 AMP group Chemical group 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 229920006227 ethylene-grafted-maleic anhydride Polymers 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- BJDYCCHRZIFCGN-UHFFFAOYSA-N pyridin-1-ium;iodide Chemical compound I.C1=CC=NC=C1 BJDYCCHRZIFCGN-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/189—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3571—Microorganisms; Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
- C12Y306/03014—H+-transporting two-sector ATPase (3.6.3.14), i.e. F1 ATPase
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Husbandry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Insects & Arthropods (AREA)
- Marine Sciences & Fisheries (AREA)
- Birds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses bacillus cereus ATP synthase beta subunit antibacterial peptide BaD, the amino acid sequence of which is KLVVHRARRIQFFLSQNFH, and the molecular weight of the antibacterial peptide is 2396.831 daltons. The antibacterial peptide has obvious inhibition effect on vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus, and can be used for preparing medicines, food preservatives or feed additives for preventing or inhibiting vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus infection.
Description
Technical Field
The invention relates to the technical field of biology, in particular to bacillus cereus ATP synthase beta subunit antibacterial peptide BaD and application thereof.
Background
Vibrio parahaemolyticusVibrio parahaemolyticus) Belongs to the genus vibrio, gram-negative bacteria, is a main pathogenic bacterium in aquaculture, is one of common five food-borne pathogenic bacteria, and can cause acute gastroenteritis when people eat marine products polluted by pathogenic vibrio parahaemolyticus. The patients can suffer from dizziness, diarrhea, abdominal cramps, vomiting, fever and the like, and even dehydration, coma and other symptoms are caused when serious. Staphylococcus aureus [ (S.aureus ]Staphylococcus aureus) Belonging to staphylococcus, gram positive bacteria, which are common polluted bacteria in food, and one of five food-borne pathogenic bacteria, can produce enterotoxin and cause food poisoning. Patients infected with staphylococcus aureus may develop symptoms such as nausea, vomiting, cramping pain in the middle and abdomen, followed by diarrhea, etc., with vomiting being prominent. LysostaphinStaphylococcus haemolyticus) The staphylococcus is gram positive bacteria, is normal field bacteria on the body surface of a human body, has the carrying rate which is inferior to that of staphylococcus epidermidis, is typical conditional pathogenic bacteria, often causes infection of patients with low immunity and patients with indwelling and implantation foreign matters, and is an important pathogen causing nosocomial infection.
Antibiotics are an important advancement in the medical history of humans for the treatment of bacterial diseases, but due to the abuse of antibiotics, bacterial resistance to antibiotics is becoming more and more serious, posing a serious threat to human health. Unlike antibiotics, which interfere with the metabolic processes of pathogenic microorganisms, antibacterial peptides mostly exert antibacterial effects by disrupting cell membranes on the surfaces of microorganisms and inducing leakage of cell contents, with minimal probability of being affected by bacterial resistance. Thus, antibacterial peptides are considered to be a good alternative to antibiotics.
Antibacterial peptides (AMPs) are a class of small molecule peptides widely existing in organisms, form a part of the first line of defense of human bodies against pathogens, and can effectively resist invasion of pathogenic microorganisms. The antibacterial peptide has the characteristics of broad-spectrum anti-biological film activity, contribution to regulating host immune response, difficult generation of drug resistance and the like, thus having unique advantages in the aspect of treating infectious diseases and being expected to become an ideal anti-infective drug. At present, antibacterial peptides have been found and isolated from bacteria, fungi, higher plants, animals, etc.
Bacillus cereus is a gram-positive, rod-shaped, and spore-forming facultative anaerobe, often found in soil, water, the intestines of animals, which can produce toxins leading to different types of gastrointestinal or other disease pathogenic bacteria. The bacillus can also produce antagonism to fungal pathogens by antibacterial, nutrition competition, site exclusion, parasitism or induction methods, and meanwhile, various active substances such as low molecular polypeptides, lipopeptides antibiotics, antibacterial proteins and the like can be produced, so that the bacillus can effectively inhibit the growth of various pathogenic microorganisms, and has good research and application values. ATP synthase subunit beta (AtpD, ATP synthase β subunit), which encodes one subunit of mitochondrial ATP synthase. Mitochondrial ATP synthase catalyzes ATP synthesis using the electrochemical gradient of protons across the inner membrane during oxidative phosphorylation. It is shown that it has an effective protective effect against psychrophilic bacteria. Therefore, searching for antibacterial peptides with antibacterial activity from beta subunit of ATP synthase of bacillus cereus and exploring the antibacterial mechanism thereof is a technical problem to be solved in the field.
Disclosure of Invention
The invention aims to overcome the defects of the prior art, provides bacillus cereus ATP synthase beta subunit antibacterial peptide BaD and application thereof, and solves the problems in the background art.
One of the technical schemes adopted for solving the technical problems is as follows: provides bacillus cereus ATP synthase beta subunit antibacterial peptide BaD, the amino acid sequence of which is shown in SEQ ID NO:1 is shown as follows:
KLVVHRARRIQFFLSQNFH
the molecular weight of the antimicrobial peptide BaD9 was 2396.831 daltons, the positive charge was +4.5, the total hydrophobicity ratio was 47%, and the peptide was predicted to form an alpha helix by APD 3.
The second technical scheme adopted by the invention for solving the technical problems is as follows: the application of the bacillus cereus ATP synthase beta subunit antibacterial peptide BaD in preparing antibacterial medicaments for inhibiting and/or killing one or more of vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus is provided.
The third technical scheme adopted by the invention for solving the technical problems is as follows: the effective components of the antibacterial medicament comprise bacillus cereus ATP synthase beta subunit antibacterial peptide BaD, and the amino acid sequence of the antibacterial peptide BaD is SEQ ID NO:1.
in a preferred embodiment of the present invention, the active ingredient of the antibacterial agent is bacillus cereus ATP synthase beta subunit antibacterial peptide BaD, and the amino acid sequence of the antibacterial peptide BaD is SEQ ID NO:1.
in a preferred embodiment of the present invention, the antibacterial agent is used for inhibiting and/or killing one or more of vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus.
The fourth technical scheme adopted for solving the technical problems is as follows: the application of bacillus cereus ATP synthase beta subunit antibacterial peptide BaD in preparing a food preservative for inhibiting and/or killing one or more of vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus is provided.
The fifth technical scheme adopted by the invention for solving the technical problems is as follows: provided is a food preservative, the active ingredients of which comprise bacillus cereus ATP synthase beta subunit antibacterial peptide BaD, the amino acid sequence of the antibacterial peptide BaD is SEQ ID NO:1.
in a preferred embodiment of the present invention, the effective component of the food preservative is bacillus cereus ATP synthase beta subunit antibacterial peptide BaD, and the amino acid sequence of the antibacterial peptide BaD is SEQ ID NO:1.
in a preferred embodiment of the present invention, the food preservative is used for inhibiting and/or killing one or more of vibrio parahaemolyticus, staphylococcus aureus, staphylococcus haemolyticus.
The sixth technical scheme adopted by the invention for solving the technical problems is as follows: the application of the bacillus cereus ATP synthase beta subunit antibacterial peptide BaD in preparing the aquatic feed additive for inhibiting and/or killing one or more of vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus is provided.
The seventh technical scheme adopted by the invention for solving the technical problems is as follows: the effective components of the aquatic feed additive comprise bacillus cereus ATP synthase beta subunit antibacterial peptide BaD, and the amino acid sequence of the antibacterial peptide BaD is SEQ ID NO:1.
in a preferred embodiment of the present invention, the effective component of the aquatic feed additive is bacillus cereus ATP synthase beta subunit antibacterial peptide BaD, and the amino acid sequence of the antibacterial peptide BaD is SEQ ID NO:1.
in a preferred embodiment of the invention, the aquatic feed additive is used for inhibiting and/or killing one or more of vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus.
The invention uses APD3, pymol2.0, SWISS-MODEL and other software and websites to carry out bioinformatics prediction by taking the protein sequence of ATP synthase beta subunit protein with antibacterial activity of bacillus cereus as an object, thus obtaining polypeptide BaD with a novel amino acid sequence. Research BaD on the antibacterial activity of vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus; and observing the damage degree of BaD to bacterial cell membrane by using flow cytometry and PI staining by taking vibrio parahaemolyticus as an example; meanwhile, the genome DNA of vibrio parahaemolyticus is extracted, and the influence of the genome DNA on bacterial DNA is verified. Experimental results show that the peptide has obvious inhibition effect on vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus. The antibacterial peptide BaD9 is a cationic antibacterial peptide, and the positive charges carried by the cationic antibacterial peptide can be combined with an anionic bacterial membrane through electrostatic interaction, so that the cationic antibacterial peptide is adsorbed on the bacterial membrane, and the potential on the cell membrane is changed to cause cell membrane damage, so that the antibacterial effect of the cationic antibacterial peptide is exerted. And the alpha-helical structure of the antibacterial peptide BaD can induce the surface of bacteria to form transmembrane pores, so as to help the antibacterial peptide to penetrate through cell membranes or leak the liposome and biomacromolecules in the cells. Therefore, whether gram positive bacteria or gram negative bacteria are adopted, the antibacterial peptide BaD and the surface of the cell membrane are combined in the same way, and the antibacterial peptide can be obtained by combining MBC and TIME-KILL TIME results and has inhibition effect on vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus.
The antibacterial peptide BaD will destroy bacteria from the following actions: the antibacterial peptide BaD can penetrate the cell membrane and combine with bacterial genomic DNA to inhibit the synthesis of bacterial DNA, thereby causing bacterial death.
The antimicrobial peptides of the invention can be synthesized using methods known to those skilled in the art, such as solid phase synthesis, and purified using methods known to those skilled in the art, such as high performance liquid chromatography.
The implementation of the invention has the following beneficial effects:
the invention discovers a polypeptide BaD9 with a brand new amino acid sequence through screening. Research BaD has remarkable inhibiting effect on vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus. The antibacterial mechanism is that the bacterial cell membrane is penetrated first and then combined with bacterial genome DNA to inhibit the synthesis of bacterial DNA, so that the bacteria die. The antibacterial peptide BaD9 can be prepared into antibacterial drugs or aquatic feed additives for preventing or treating diseases caused by infection of vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus.
Drawings
FIG. 1 is a schematic structural diagram of an antibacterial peptide BaD.
FIG. 2 is a graph showing a control of the Minimum Bactericidal Concentration (MBC) of the antibacterial peptide BaD against Vibrio parahaemolyticus.
Wherein the concentrations of the antibacterial peptide BaD shown in the diagrams A-I are 0 μg/mL, 500 μg/mL, 250 μg/mL, 125 μg/mL, 62.5 μg/mL, 31.25 μg/mL, 15.625 μg/mL, 7.813 μg/mL and 3.9 μg/mL, respectively
FIG. 3 is a graph showing a control of the Minimum Bactericidal Concentration (MBC) of the antibacterial peptide BaD against Staphylococcus hemolyticus.
Wherein the concentrations of the antibacterial peptide BaD shown in the diagrams A-I are 0 μg/mL, 500 μg/mL, 250 μg/mL, 125 μg/mL, 62.5 μg/mL, 31.25 μg/mL, 15.625 μg/mL, 7.813 μg/mL and 3.9 μg/mL, respectively
FIG. 4 is a graph showing a control of Minimum Bactericidal Concentration (MBC) of the antibacterial peptide BaD against Staphylococcus aureus.
Wherein the concentrations of the antibacterial peptide BaD shown in the diagrams A-I are 0 μg/mL, 500 μg/mL, 250 μg/mL, 125 μg/mL, 62.5 μg/mL, 31.25 μg/mL, 15.625 μg/mL, 7.813 μg/mL and 3.9 μg/mL, respectively
FIG. 5 is a graph showing the time-based killing kinetics of the antibacterial peptide BaD against Vibrio parahaemolyticus.
FIG. 6 is a graph showing the time-kill kinetics of the antimicrobial peptide BaD against Staphylococcus hemolyticus.
Fig. 7 is a time kill kinetics plot of the antimicrobial peptide BaD against staphylococcus aureus.
FIG. 8 shows the effect of antibacterial peptide BaD9 on Vibrio parahaemolyticus cell membrane permeability (protein leakage).
FIG. 9 is an effect of antibacterial peptide BaD9 on Vibrio parahaemolyticus cell membrane permeability.
FIG. 10 is a graph showing the circular dichroism spectrum of the antibacterial peptide BaD under different conditions.
FIG. 11 is a gel electrophoresis chart of the antibacterial peptide BaD and Vibrio parahaemolyticus genomic DNA.
Wherein, the mass ratio of the antibacterial peptide BaD/DNA in the bands 1-9 is respectively as follows: 25/4, 25/8, 25/10, 25/12, 25/14, 25/16, 25/18, 25/20, 25/25;
band 10 is control DNA.
FIG. 12 is a graph showing a circular dichroism spectrum after binding of the antibacterial peptide BaD to the Vibrio parahaemolyticus genomic DNA.
Detailed Description
For a better understanding of the present invention, reference will now be made in detail to the following examples and accompanying drawings, which are included to provide a further understanding of the invention, and it is to be understood by those skilled in the art that the following examples are not intended to limit the scope of the invention.
The experimental methods used in the following examples are conventional methods unless otherwise specified.
Materials, reagents and the like used in the examples described below are commercially available unless otherwise specified.
Example 1 screening of antibacterial peptide BaD9
The biological informatics prediction is carried out by using software such as APD3, pymol2.0 and SWISS-MODEL, and websites by taking the protein sequence of ATP synthase beta subunit protein with antibacterial activity of bacillus cereus as an object, the amino acid sequence is used for analyzing the charge and hydrophobicity of the protein by using APD3 (table 1), the three-dimensional structure is predicted by using Pymol2.0 and SWISS-MODEL (shown in figure 1), and finally the amino acid sequence KLVVHRARRIQFFLSQNFH with the antibacterial performance is screened out and chemically synthesized (synthesized by Beijing middle family matte biotechnology Co., ltd.) and the antibacterial activity is verified.
Table 1: predictive analysis of antibacterial peptides in bacillus cereus
| Peptide fragment sequences | Molecular weight (Da) | Water repellency ratio | Number of net charges | Source (protein) |
| KLVVHRARRIQFFLSQNFH | 2396.831 | 47% | +4.5 | ATP synthase subunit beta |
Example 2 Minimum Bactericidal Concentration (MBC) assay of antibacterial peptide BaD9
Vibrio parahaemolyticus, goldStaphylococcus aureus and staphylococcus hemolyticus (Vibrio parahaemolyticus ATCC17802, staphylococcus aureus ATCC27217, staphylococcus haemolyticus JCM2416, all the laboratory preservation strain) are cultured at 37 ℃ for 12 h to logarithmic phase, and diluted to 10 in 0.01M pH 7.2 phosphate buffer 5-6 CFU/mL. Antibacterial peptide BaD was dissolved in phosphate buffer, mixed with bacteria in equal volume at 37 ℃ and incubated 2 h. The minimum inhibitory concentration (MBC) refers to the minimum concentration of antimicrobial peptide that kills bacteria after incubation at 37 ℃. As shown in fig. 2-4, the Minimum Bactericidal Concentration (MBC) of the antibacterial peptide BaD on vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus is 3.90625 μg/mL, 7.8125 μg/mL and 7.8125 μg/mL respectively.
Example 3 Time-sterilization Curve (Time kill) determination of antibacterial peptide BaD9
Culturing vibrio parahaemolyticus, staphylococcus haemolyticus, and staphylococcus aureus at 37deg.C for 12-h to logarithmic phase, and diluting to 10 in 0.01M pH 7.2 phosphate buffer 5-6 CFU/mL. The 1 XMBC concentration peptide was mixed with bacteria in equal volumes at 37℃and incubated, the plates were sampled and plated every 30 minutes, and the total number of colonies was recorded after incubation at 37℃overnight. From the results, it was found that the antibacterial peptides killed Vibrio parahaemolyticus, staphylococcus haemolyticus, and Staphylococcus aureus within 0.5 hour. (as shown in FIG. 5 to 7)
Example 4 Effect of antibacterial peptide BaD9 on Vibrio parahaemolyticus cell membrane permeability
Protein leakage: 200 mu L of the Vibrio parahaemolyticus strain preserved at-20 ℃ is inoculated into LB culture medium, and shake culture is carried out at 37 ℃ and 200 r/h for 10 h to the logarithmic growth phase of bacteria. After preparing a bacterial suspension of 0.01. 0.01M phosphate buffer, the bacterial suspension was mixed with antibacterial peptide BaD9 having 1 XMBC, 2 XMBC and 4 XMBC concentrations in equal proportions, and the protein leakage amount of the bacterial cells was examined at OD280 nm every 10 min for 0 to 2 h using a multifunctional microplate reader. The experiment was performed with equal amounts of 0.01. 0.01M phosphate buffer and bacteria as a blank (as shown in fig. 8).
280 Detection of absorbance at nm can be used to estimate the amount of protein leaking from the cytoplasm. As shown in fig. 8, the amount of protein in the culture solution treated with the antibacterial peptide BaD increased in a dose-dependent manner as the concentration of the antibacterial peptide BaD increased.
Flow cytometry: culturing Vibrio parahaemolyticus at 37deg.C for 12 h to logarithmic phase, centrifuging 1. 1 mL strain solution in a 1.5 mL centrifuge tube at 12000 r/min for 1 min, removing supernatant, and re-suspending to 1 mL sterile 0.01M phosphate buffer solution, and repeating for 3 times. After preparing a bacterial suspension of 0.01. 0.01M phosphate buffer, antibacterial peptide BaD9 having a concentration of 1 XMBC and 2 XMBC was mixed with the bacterial solution in equal proportions (more than 200. Mu.L), and the mixture was placed in a biochemical incubator at 37℃and incubated at 2 h, and 0.01M phosphate buffer was used as a blank control. Pyridine Iodide (PI) is used as a fluorescent dye, the PI dye with the equal volume concentration of 50 mug/mL is added into the mixed solution after the incubation is completed, and after the incubation is carried out for 15 min at 4 ℃, the sample is loaded to a flow cytometer for detection. Detecting each tube is set to obtain at least 10 4 Bacterial cells. A data collection analysis protocol was set up to analyze the samples by detecting scattered light Signals (SC) and propidium iodide fluorescent signals (PI) (as shown in fig. 9).
As shown in fig. 9, the control group has a vibrio parahaemolyticus mortality rate of only 9.95%, which indicates that the cell membrane structure is complete, PI cannot penetrate the cell membrane to enter the cell interior, and the bacterial mortality rate is low; the death rate of the vibrio parahaemolyticus added with the antibacterial peptide BaD9 with the concentration of 1 XMBC is obviously increased to 89.8 percent; vibrio parahaemolyticus mortality in the experimental group to which 2 XMBC concentration of antibacterial peptide was added was slightly increased to 94.6% compared to 1 XMBC. It can be seen that the concentration of the antibacterial peptide BaD positively correlated with the mortality rate of Vibrio parahaemolyticus and increased in a dose-dependent manner.
Example 5 round dichroism determination of antibacterial peptide BaD secondary Structure
The average residue molar ellipticity of the antimicrobial peptide BaD was determined using a Jasco810 spectropolarimeter (Jasco, tokyo) CD at 25℃at a scan rate of 100 nm/min. Antibacterial peptide BaD is dissolved in 0.01M PBS and 25mM Sodium Dodecyl Sulfate (SDS) respectively to make the final concentration of the antibacterial peptide be 0.20 mg/mL, and the spectrum of the antibacterial peptide is scanned from 180 nm to 280 nm by twice scanning.
As shown in fig. 10, in PBS environment, the antibacterial peptide BaD exhibited a positive peak at 198 and nm and a negative peak at 225nm, indicating that the antibacterial peptide BaD9 was predominantly β -folded in its secondary conformation in PBS environment. In the SDS environment, there is a positive peak at 190nm, and two negative peaks appear at 211 nm, 220 nm, which indicates that the secondary conformation is mainly an alpha-helix in the SDS environment, and the antibacterial peptide may undergo structural transformation when contacting with bacterial cell membranes.
Example 6 interaction of antibacterial peptide BaD9 with bacterial DNA
The interaction of the antibacterial peptide BaD with Vibrio parahaemolyticus genomic DNA was investigated using a DNA gel blocking method. Vibrio parahaemolyticus was cultured in 50 mL nutrient broth medium at 37℃for 12 h, and the ratio of optical density of bacteria 260 and 280 nm (OD 260 /OD 280 1.90) the purity of the extracted genomic DNA was evaluated. Next, 10. Mu.L of DNA (20 ng/. Mu.L) was mixed with the antimicrobial peptide BaD at 25℃so that the antimicrobial peptide BaD/DNA mass ratio was 25/4, 25/8, 25/10, 25/12, 25/14, 25/16, 25/18, 25/20, 25/25, 0, respectively, and incubated at 37℃for 1.5 h after mixing. Then 8 μl of each was taken for electrophoresis on a 1% agarose gel and gel blocking was observed under ultraviolet irradiation using a GelDoc XR gel imaging system (Bio-Rad, usa).
As shown in FIG. 11, the DNA bands did not run out at the ratios of 25/4, 25/8, 25/10, 25/12, but remained significantly in the wells, and the band clarity and brightness increased significantly with decreasing ratios of 25/14, 25/16, 25/18, 25/20, 25/25, respectively; gel electrophoresis of the control Vibrio parahaemolyticus genomic DNA is shown as the brightest and clear band. The antibacterial peptide BaD/DNA mass ratio is shown as follows: 25/4, 25/8, 25/10, 25/12, the DNA is blocked and destroyed, the band does not run out, but the band gradually and clearly runs out as the concentration of the antimicrobial peptide decreases.
Example 7 Effect of antibacterial peptide BaD9 on the secondary Structure of bacterial DNA
The average residue molar ellipticity of the antimicrobial peptide BaD was determined again using a Jasco810 spectropolarimeter (Jasco, tokyo) CD at 25 ℃ at a scan rate of 100 nm/min. Antibacterial peptide BaD was dissolved in 25mM Sodium Dodecyl Sulfate (SDS) to give a final concentration of 0.20: 0.20 mg/mL, and after mixing Vibrio parahaemolyticus DNA (20: 20 ng/. Mu.L) with antibacterial peptide BaD9 at 25℃and incubating for 2 h, the spectrum was scanned from 180 to 280 nm by two scans (shown in FIG. 12).
After the DNA is incubated with the antibacterial peptide BaD9, the secondary structure of the antibacterial peptide is changed, the positive peak is changed from 190nm to 195 nm, the negative peak is changed from 211 nm and 220 nm to the single negative peak at 217 nm, the secondary structure is changed from an alpha-helical structure to a beta-sheet structure, and the spectrogram of the antibacterial peptide BaD9 is integrally expanded, so that the interaction relationship between the antibacterial peptide BaD9 and the vibrio parahaemolyticus genomic DNA exists, and the secondary structure conformation of the antibacterial peptide can be changed.
In summary, the invention provides a brand new antibacterial peptide BaD, wherein the Minimum Bactericidal Concentration (MBC) of the antibacterial peptide BaD on vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus is 3.90625 mug/mL, 7.8125 mug/mL and 7.8125 mug/mL respectively, and vibrio parahaemolyticus, staphylococcus haemolyticus and staphylococcus aureus can be killed within 0.5 hour, which shows that the antibacterial peptide BaD has a strong inhibition effect on vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus. According to research, the antibacterial peptide BaD9 can penetrate through cell membranes of bacteria, and can be combined with bacterial genome DNA to inhibit synthesis of the bacterial DNA, so that the bacteria die.
While specific embodiments of the invention have been described above, it will be appreciated by those skilled in the art that the specific embodiments described are illustrative only and not intended to limit the scope of the invention, and that equivalent modifications and variations of the invention in light of the spirit of the invention will be covered by the claims of the present invention.
Claims (13)
1. An antibacterial peptide BaD of beta subunit of ATP synthase of bacillus cereus, which has an amino acid sequence shown in SEQ ID NO:1.
2. The use of bacillus cereus ATP synthase beta subunit antibacterial peptide BaD9 of claim 1 for the manufacture of an antibacterial medicament, wherein: the antibacterial drug is used for inhibiting and/or killing one or more of vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus.
3. An antibacterial agent characterized in that: the active ingredients of the bacillus cereus ATP synthase beta subunit antibacterial peptide BaD, and the amino acid sequence of the antibacterial peptide BaD is SEQ ID NO:1.
4. an antimicrobial agent as claimed in claim 3 wherein: the active ingredient of the antibacterial peptide is bacillus cereus ATP synthase beta subunit antibacterial peptide BaD, and the amino acid sequence of the antibacterial peptide BaD is SEQ ID NO:1.
5. the antibacterial agent according to any one of claims 3 or 4, wherein: the antibacterial drug is used for inhibiting and/or killing one or more of vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus.
6. The use of bacillus cereus ATP synthase beta subunit antibacterial peptide BaD9 of claim 1 for the preparation of a food preservative, wherein: the food preservative is used for inhibiting and/or killing one or more of vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus.
7. A food preservative characterized by: the active ingredients of the bacillus cereus ATP synthase beta subunit antibacterial peptide BaD, and the amino acid sequence of the antibacterial peptide BaD is SEQ ID NO:1.
8. the food preservative according to claim 7, characterized in that: the active ingredient of the antibacterial peptide is bacillus cereus ATP synthase beta subunit antibacterial peptide BaD, and the amino acid sequence of the antibacterial peptide BaD is SEQ ID NO:1.
9. the food preservative according to any one of claims 7 or 8, characterized in that: the antibacterial drug is used for inhibiting and/or killing one or more of vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus.
10. The use of bacillus cereus ATP synthase beta subunit antibacterial peptide BaD9 of claim 1 for the preparation of an aquatic feed additive, wherein: the aquatic feed additive is used for inhibiting and/or killing one or more of vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus.
11. An aquatic feed additive, characterized in that: the active ingredients of the bacillus cereus ATP synthase beta subunit antibacterial peptide BaD, and the amino acid sequence of the antibacterial peptide BaD is SEQ ID NO:1.
12. an aquatic feed additive as claimed in claim 11 wherein: the active ingredient of the antibacterial peptide is bacillus cereus ATP synthase beta subunit antibacterial peptide BaD, and the amino acid sequence of the antibacterial peptide BaD is SEQ ID NO:1.
13. an aquaculture feed additive according to any one of claims 11 or 12 wherein: the aquatic feed additive is used for inhibiting and/or killing one or more of vibrio parahaemolyticus, staphylococcus aureus and staphylococcus haemolyticus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310034176.8A CN116622670A (en) | 2023-01-10 | 2023-01-10 | Bacillus cereus ATP synthase beta subunit antibacterial peptide BaD and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310034176.8A CN116622670A (en) | 2023-01-10 | 2023-01-10 | Bacillus cereus ATP synthase beta subunit antibacterial peptide BaD and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116622670A true CN116622670A (en) | 2023-08-22 |
Family
ID=87590780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310034176.8A Pending CN116622670A (en) | 2023-01-10 | 2023-01-10 | Bacillus cereus ATP synthase beta subunit antibacterial peptide BaD and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116622670A (en) |
-
2023
- 2023-01-10 CN CN202310034176.8A patent/CN116622670A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZÄHNER | THE NEED FOR NEW ANTIBIOTICS: POSSIBLE WAYS FORWARD HANS ZÄHNER AND HANS-PETER FIEDLER | |
| Arunachalam et al. | Studies on bioprospecting of endophytic bacteria from the medicinal plant of Andrographis paniculata for their antimicrobial activity and antibiotic susceptibility pattern | |
| CN114134083B (en) | Bacillus bailii and application thereof | |
| US20230416312A1 (en) | Process for the preparation of an antimicrobial peptide | |
| CN112898386A (en) | Large yellow croaker myosin heavy chain antibacterial peptide LCMHC and application thereof | |
| CN104945484B (en) | A kind of antibacterial peptide and preparation method and application | |
| CN110156875B (en) | Antibacterial peptide H5-p5, and preparation method and application thereof | |
| CN115536737A (en) | Application of cobra antibacterial peptide OH-CATH30 in resisting aquatic animal pathogenic bacteria | |
| CN113321708B (en) | Preparation of artificially designed antibacterial peptide and application of artificially designed antibacterial peptide in aquatic products | |
| Chi et al. | Biosurfactins production by Bacillus amyloliquefaciens R3 and their antibacterial activity against multi-drug resistant pathogenic E. coli | |
| CN112812159B (en) | Yeast polypeptide derived from saccharomyces boulardii as well as preparation method and application thereof | |
| CN116731153B (en) | Pig beta-interferon antibacterial peptide IFN7 and application thereof | |
| CN106632606B (en) | Antibacterial lipopeptide bacaucin derivative and application thereof in inhibiting bacterial infection | |
| CN117164665A (en) | Human nasal fluid alpha-2-macroglobulin antibacterial peptide A2M3 and application thereof | |
| CN106883288B (en) | Antibacterial peptide BV21 and application thereof | |
| CN116640186A (en) | Human nasal fluid complement factor antibacterial peptide C4-AII and application thereof | |
| CN113087771B (en) | Penaeus vannamei DNA (deoxyribonucleic acid) combined antibacterial peptide VPDB40 and application thereof | |
| CN116622670A (en) | Bacillus cereus ATP synthase beta subunit antibacterial peptide BaD and application thereof | |
| KR20210001106A (en) | Bacillus subtilis BSC35 strain having antimicrobial activity and uses thereof | |
| Bino et al. | Assessment of biofilm formation by faecal strains of Enterococcus hirae from different species of animals | |
| CN116121221B (en) | Bacillus cereus DEAD-box RNA helicase protein antibacterial peptide DB16 and application thereof | |
| CN109627285B (en) | Galactococcus anomala antibacterial peptide and application thereof | |
| Lueders et al. | Unusual outbreak of fatal clostridiosis in a group of captive brown pelicans (Pelecanus occidentalis) | |
| CN116121221A (en) | Bacillus cereus DEAD-box RNA helicase protein antibacterial peptide DB16 and application thereof | |
| CN106883289B (en) | Antibacterial peptide BV21 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |